Several bulk deals took place in Balaxi Pharmaceuticals Ltd and Praxis Home Retail Ltd. Bulk deals are large transactions, typically involving major investors, which can influence stock prices. Domestic institutional investors (DIIs) bought and sold shares, indicating strong interest in these companies.
Here are a few bulk deals that took place on April 4, 2025.
Praxis Home Retail Limited
Praxis Home Retail Limited was established in 2007 and is based in Mumbai, India. The company specializes in home retailing through its HomeTown stores and online platform. It offers furniture, home décor, modular kitchens, and customized interior solutions, catering to diverse customer needs.
Stock Price Movement
With a market capitalization of Rs. 184.61 crores, the share of Praxis Home Retail Limited has reached an intraday high of Rs. 10.30 per equity share, rising nearly 3.94 percent from its previous day’s close price of Rs. 9.91. Since then, the stock has retreated and is currently trading at Rs. 9.99 per equity share.
What Happened
On April 4, 2025, India Opportunities Growth Fund Limited – Pinewood Strategy purchased 12 lakh shares of the company at an average price of Rs. 10.10 per share, totaling Rs. 1.21 crore. The shares were acquired from Sapiens Alpha Growth Fund in a bulk deal transaction.
Recent quarter results
Praxis Home Retail Limited’s revenue has decreased from Rs. 64.04 crore in Q3 FY24 to Rs. 33.96 crore in Q3 FY25, which has decreased by 46.97 percent. The net loss of the company has reduced from Rs. -18.55 crore in Q3 FY24 to Rs. -8.3 crore in Q3 FY25.
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited was established in 2004 and is an India-based IPR-driven pharma firm. It operates in Latin America and Africa, offering branded and generic medicines across various therapeutic segments with a global presence.
Stock Price Movement
With a market capitalization of Rs. 344.55 crore, the shares of Balaxi Pharmaceuticals Limited were currently trading at Rs. 62.41 per equity share, down nearly 6.86 percent from its previous day’s close price of Rs. 67.01.
What Happened
On April 4, 2025, EBISU Global Opportunities Fund Limited sold 2.98 lakh shares of the company in a bulk deal at an average price of Rs. 67.50 per share, totaling Rs. 2.01 crore for the transaction.
Recent quarter results
Balaxi Pharmaceuticals Limited’s revenue has increased from Rs. 60.79 crore in Q3 FY24 to Rs. 73.29 crore in Q3 FY25, which has grown by 20.56 percent. The net profit has decreased by 60.56 percent from Rs. 13.59 crore in Q3 FY24 to Rs. 5.36 crore in Q3 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
